{
    "2018-01-16": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Teva's Trisenox Gets FDA Approval as First-Line Treatment",
                "features": {
                    "keywords": [
                        "Teva",
                        "Trisenox",
                        "FDA Approval",
                        "First-Line Treatment"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Risks",
                        "Underappreciated",
                        "Goldman Sachs",
                        "Downgrade"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-05-20",
                "original_text": "The Race To Find A Treatment For NASH",
                "features": {
                    "keywords": [
                        "Race",
                        "Treatment",
                        "NASH"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}